In July 2022, Epigral commissioned CPVC Resin capacity of 30,000 TPA. This was followed by the company announcing further increase in capacity to 75,000 TPA by Q4 FY24, a part of which will be utilised for CPVC compound manufacturing with an additional capex of Rs 25 crore.

With this expansion, Epigral will be catering to both, CPVC Resin and CPVC Compound customers in the country.

Resistant to high heat and chemicals, CPVC Resin is widely used in manufacturing pipes for industrial and domestic purposes. India is net importer of CPVC Resin and CPVC Compound demand. With Epigral venturing into manufacturing CPVC Compounds, the company aims at adding to domestic supply volume, thereby contributing in bridging the demand and supply gap.

Maulik Patel, chairman & managing director, Epigral, said: “We have been expansively contributing to this market for over a year now, which has enabled us to gather invaluable market and sector insights. Intensified growth of construction industry in India, along with growing applications of CPVC, presents with immense growth opportunities.”

Epigral, formerly known as Meghmani Finechem, is an integrated manufacturer of chemicals in India. In India, Epigral is the first to set up an epichlorohydrin plant and largest capacity plant of CPVC Resin. Epigral is India's fourth largest manufacturer of caustic soda, chlorine and hydrogen and a leading manufacturer of caustic potash, chloromethanes and hydrogen peroxide.

The company's consolidated net profit declined 70.77% to Rs 31.51 crore on a 14.63% fall in sales to Rs 454.89 crore in Q1 FY24 as compared with Q1 FY23.

The scrip fell 2.77% to currently trade at Rs 1000 on the BSE.